Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia.
Yağci
M
M
Sucak
G T
GT
Haznedar
R
R
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006515:Hepatitis B virus / Q000254:growth & development / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000821:virology*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014775:Virus Activation / Q000502:physiology; D014779:Virus Replication
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D014740:Vidarabine; C024352:fludarabine